Janux Therapeutics (JANX) Operating Leases (2021 - 2026)

Janux Therapeutics (JANX) has reported Operating Leases for 6 consecutive years, with $19.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 8.18% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $19.1 million (down 8.18% YoY), while the FY2025 annual figure was $19.7 million, down 7.19% from the prior year.
• Operating Leases eased to $19.1 million in Q1 2026 per JANX's latest filing, from $19.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $24.5 million in Q4 2022 and bottomed at $19.1 million in Q1 2026.
• Historically, Operating Leases has averaged $22.2 million across 5 years, with a median of $22.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases soared 104647.83% — and 2025, when it decreased 8.44%.
• Janux Therapeutics' Operating Leases stood at $24.5 million in 2022, then declined by 6.18% to $23.0 million in 2023, then declined by 7.6% to $21.3 million in 2024, then dropped by 7.19% to $19.7 million in 2025, then decreased by 3.28% to $19.1 million in 2026.
• Business Quant data shows JANX's Operating Leases at $19.1 million in Q1 2026, $19.7 million in Q4 2025, and $20.4 million in Q3 2025.